Back to Journals » Neuropsychiatric Disease and Treatment » Volume 7 » Issue 1

Choking risk among psychiatric inpatients

Authors Briley M

Published 20 June 2011 Volume 2011:7(1) Pages 381—382

DOI https://doi.org/10.2147/NDT.S22419

Takahiko Nagamine
1Division of Psychiatric Internal Medicine, Seiwakai-Kitsunan Hospital, Suzenji, Japan

Choking is a life-threatening and not infrequent occurrence in psychiatric hospitals. There is, however, little information available about the risk factors or methods to prevent choking. We conducted a retrospective analysis of the 8 patients who had a cardiopulmonary arrest due to choking and received resuscitation at our hospital during the 6-year period from April 2005 to March 2011. The study involved 6 males and females, all of whom were patients with schizophrenia taking antipsychotics orally. They were aged from 56 to 79 (mean ± SD: 69.0 ± 7.5 years), with the duration of illness from 28 to 54 years (39.9 ± 7.9 years). In 6 of the 8 cases, choking was diagnosed immediately on the basis of the situation at the time of cardiopulmonary arrest. In the remaining 2 cases, cardiopulmonary arrest was initially unexplained, and choking was only diagnosed subsequently. Choking was caused by bread in all cases. Tracheal intubation was carried out in all cases and resulted in successful resuscitation, causing no subsequent change in functions compared with the prechoking condition. All 8 patients had been receiving multiple antipsychotics before the event (mean number of drugs used 2.5 ± 0.7), with a total dose level ranging from 600 to 1800 mg/day chlorpromazine equivalents (mean 1113 ± 341 mg/day). Seven of the 8 patients had mild to moderate involuntary movements, and 5 patients were diagnosed with antipsychotic-induced tardive dyskinesia. During the 5-year period before the choking event, 7 of the 8 patients had at least 1 treatment interruption, and some patients had up to 4 interruptions.

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]

 

Other articles by this author:

Noradrenergic symptom cluster in depression

Montgomery S, Briley M

Neuropsychiatric Disease and Treatment 2011, 7:1-2

Published Date: 31 May 2011

Improvement of the noradrenergic symptom cluster following treatment with milnacipran

Kasper S, Meshkat D, Kutzelnigg A

Neuropsychiatric Disease and Treatment 2011, 7:21-27

Published Date: 31 May 2011

The increasing burden of depression

Lépine J-P, Briley M

Neuropsychiatric Disease and Treatment 2011, 7:3-7

Published Date: 31 May 2011

The importance of norepinephrine in depression

Moret C, Briley M

Neuropsychiatric Disease and Treatment 2011, 7:9-13

Published Date: 31 May 2011

Antidepressant therapy with milnacipran and venlafaxine

Lucilla Mansuy

Neuropsychiatric Disease and Treatment 2010, 6:17-22

Published Date: 25 August 2010

Milnacipran: a unique antidepressant?

Siegfried Kasper, Gerald Pail

Neuropsychiatric Disease and Treatment 2010, 6:23-31

Published Date: 25 August 2010

Milnacipran: recent findings in depression

Guest editors: Stuart Montgomery (London, UK) and Mike Briley (Castres, France)

Neuropsychiatric Disease and Treatment 2010, 6:0-0

Published Date: 24 August 2010

Editorial Foreword - Milnacipran: recent findings in depression

Stuart Montgomery, Mike Briley

Neuropsychiatric Disease and Treatment 2010, 6:1-2

Published Date: 24 August 2010

Readers of this article also read:

Emerging and future therapies for hemophilia

Carr ME, Tortella BJ

Journal of Blood Medicine 2015, 6:245-255

Published Date: 3 September 2015

A new recombinant factor VIII: from genetics to clinical use

Santagostino E

Drug Design, Development and Therapy 2014, 8:2507-2515

Published Date: 12 December 2014

Green synthesis of water-soluble nontoxic polymeric nanocomposites containing silver nanoparticles

Prozorova GF, Pozdnyakov AS, Kuznetsova NP, Korzhova SA, Emel’yanov AI, Ermakova TG, Fadeeva TV, Sosedova LM

International Journal of Nanomedicine 2014, 9:1883-1889

Published Date: 16 April 2014

Methacrylic-based nanogels for the pH-sensitive delivery of 5-Fluorouracil in the colon

Ashwanikumar N, Kumar NA, Nair SA, Kumar GS

International Journal of Nanomedicine 2012, 7:5769-5779

Published Date: 15 November 2012

Cross-linked acrylic hydrogel for the controlled delivery of hydrophobic drugs in cancer therapy

Deepa G, Thulasidasan AK, Anto RJ, Pillai JJ, Kumar GS

International Journal of Nanomedicine 2012, 7:4077-4088

Published Date: 27 July 2012

Crystallization after intravitreal ganciclovir injection

Pitipol Choopong, Nattaporn Tesavibul, Nattawut Rodanant

Clinical Ophthalmology 2010, 4:709-711

Published Date: 14 July 2010